InvestorsHub Logo
Followers 3
Posts 276
Boards Moderated 0
Alias Born 12/21/2022

Re: None

Saturday, 04/29/2023 9:24:17 AM

Saturday, April 29, 2023 9:24:17 AM

Post# of 3283
Reading about ASRT. In 4thQ earning call Dan Peisert, a CEO of Assertio, provided a guidance on Indocin sales in 2023. He said, expect north of $100M, same as in previous year. Good to know, since Indocin is not patent protected drug.
He was asked about their BD strategy. Here is what he said about current assets valuation, "It really -- it's asset by asset. But, I think the generalization I can give is, that they're far more reasonable than they were in 2008, when I started doing this, and we were paying five times revenue. So I think the valuation perceptions of the sellers are reasonable and they've come in check. And we're seeing, a very large amount of very attractive opportunities." So, they paid for Rolvedon ~$250M. If they would be paying this price in 2008, they would be expecting sales of Rolvedon at $50M/year. Ridiculously low. I guess, it is really good deal for them.